BMS and Jiangsu Hengrui Sign 15.2 Billion Dollar Agreement
Jiangsu Hengrui and Bristol Myers Squibb signed deals worth up to 15.2 billion dollars. The 13 early-stage programs focus on cancer and immunology treatments.
X24 AnalysisX24 AnalysisX24 AnalysisX24 Analysis